Received Mar 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
Patient took third dose of Vivotif 12 hours later (on day six instead on day five); Case reference number US-BN-2024-001980 is a spontaneous case initially received from a pharmacist via Communications (reference number: USBAV23-1229) on 03-Jun-2024 and concerns a male patient of unspecified age. The patient's relevant medical history and concomitant medications were not provided. On unspecified date, reported as day one, the patient took first dose of Vivotif (batch number: unknown), at an unknown dose, orally, for typhoid immunisation. On unspecified date, reported as day three, the patient took second dose of Vivotif (batch number: unknown), at an unknown dose, orally. On unspecified date, reported as day six and as 12 hours late, the patient took third dose of Vivotif instead on day five (batch number: Unknown), at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240603-af18b1 to US-BAVARIAN NORDIC A/S-US-BN-2024-001980, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A male patient of unspecified age took third dose of Vivotif six and as 12 hours late, at an unknown dose, orally which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medications were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A male patient of unspecified age took third dose of Vivotif six and as 12 hours late, at an unknown dose, orally which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medications were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None